# Artiospharma

**Canonical:** https://apis.io/providers/artiospharma/  
**Website:** https://www.artios.com  
**APIs profiled:** 0

Artios Pharma is a clinical‑stage oncology company focused on DNA Damage Response (DDR) medicines. It develops novel cancer therapies targeting DDR pathways, aiming to deliver meaningful survival benefits to patients with limited treatment options. The company’s pipeline includes ATR inhibitor alnodesertib, Pol Theta inhibitor ART6043, and DDR‑i‑ADC ART21934, supported by a strong scientific team and investors.

## Kin Score — 8.9 / 100 (minimal)

Scored 2026-10-23 under rubric 0.25.0. Trend: flat (+0.0 from 8.9).

| Facet | Score |
|---|---|
| Discoverability | 48.2 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 10.9 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **Artiospharma Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Oncology, Biotechnology, DDR, Clinical Stage

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/artiospharma/). Scores are computed from the provider's own public artifacts under a published rubric.